Astrazeneca Stock News

Alexion, AstraZeneca’s Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an

AstraZeneca PLC (LSE:AZN) shares jumped this morning after it announced an exclusive US$760mln deal with Neurimmune to develop a drug to combat heart disease. The collaboration and licensing agreement

Through the VCC, Zyla has bridged the gap between access to quality care and the holisticness of empathetic care delivery to ensure improved patient outcomes.

Many healthcare stocks have been outperforming the market averages this year. Here are three stocks our roundtable likes.

In recent trading session, AstraZeneca PLC (NASDAQ:AZN) saw 2.54 million shares changing hands at last check today with its beta currently measuring 0.48. Company’s recent per share price level of $60.34 trading at $2.21 or 3.80% at last check today assigns it a market valuation of $182.26B. That most recent trading price of AZN’s stock … AstraZeneca PLC (NASDAQ:AZN) Has Reached A Distance Of 22.97% From Its Low, So Is It Poised For More Gains? Read More »

The FDA authorized an increased dose in the case of AstraZeneca Plc''s (NASDAQ: AZN ) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab). "Based on the most recent information and data available, Evusheld may be less active against certain Omicron subvariants. The dosing regimen was revised because available data indicate that a higher dose of Evusheld may be more likely to prevent infection by the COVID-19 Omicron subvariants BA.1 and BA.1.1 than the originally authorized Evusheld dose," the FDA said … Full story available on Benzinga.com

Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.

Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.

The approval gives people who are hesitant to take currently available vaccines made by Pfizer Inc., AstraZeneca Plc and Moderna Inc. another option.

Covid-19 vaccine: The approval gives people who are hesitant to take currently available vaccines made by Pfizer Inc., AstraZeneca Plc and Moderna Inc. another option

Nearly two million were AstraZeneca shots that advisers said should not be given to younger adults.

Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter. Stock gains in pre-market.

AstraZeneca (AZN) inked a conditional agreement with Canada to supply 100K doses of its antibody therapy Evusheld for the prevention (pre-exposure prophylaxis) of COVID-19.The…

Here are four pharma stocks that looks attractive for the long-term. Deep product development pipelines will ensure steady revenue and cash flow growth.